Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

NIH 4 OTHER 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Ovarian Neoplasms 7 Uterine Cervical Neoplasms 2 Rectal Neoplasms 2 Endometrial Neoplasms 2 Uveal Melanoma 1 Sarcoma, Alveolar Soft Part 1 Sarcoma 1 Pleural Effusion, Malignant 1 Neoplasms 1 Neoplasm Metastasis 1 Lung Neoplasms 1 Leiomyosarcoma 1 Gliosarcoma 1 Glioblastoma 1 Fallopian Tube Neoplasms 1 Colorectal Neoplasms 1 Colonic Neoplasms 1 Carcinosarcoma 1 Carcinoma, Renal Cell 1 Carcinoma, Non-Small-Cell Lung 1 Breast Neoplasms 1 Brain Neoplasms 1 Biliary Tract Neoplasms 1

Interventions

Nivolumab 74 Sunitinib 73 pembrolizumab 49 Everolimus 39 Sorafenib 36 Bevacizumab 36 Axitinib 36 cabozantinib 35 Radiosurgery 33 Ipilimumab 33 pazopanib 32 Magnetic Resonance Spectroscopy 27 Interleukin-2 27 aldesleukin 23 Specimen Handling 22 Cyclophosphamide 21 lenvatinib 20 fludarabine phosphate 17 Radiotherapy 16 Interferon-alpha 15 Peripheral Blood Stem Cell Transplantation 14 Gemcitabine 14 Biopsy 14 temsirolimus 13 Nephrectomy 13 durvalumab 11 Immunohistochemistry 11 CTLA-4 Antigen 11 Blood Specimen Collection 11 Capecitabine 10

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Carcinoma, Renal Cell × cediranib × Clear all

NCT03741426 2023-06-07

WIRE

Cambridge University Hospitals NHS Foundation Trust

Phase 2 Unknown

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡